|Application ||WB, IHC-P, IF, E|
|Other Accession||NP_006294, 11125770|
|Calculated MW||Predicted: 35 kDa |
Observed: 36 kDa
|Application Notes||AIMP2 antibody can be used for detection of AIMP2 by Western blot at 1 - 2 µg/ml.|
|Target/Specificity||AIMP2; AIMP2 antibody is human specific. AIMP2 antibody is predicted to not cross-react with AIMP1.|
|Reconstitution & Storage||AIMP2 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year.|
|Precautions||AIMP2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Required for assembly and stability of the aminoacyl- tRNA synthase complex. Mediates ubiquitination and degradation of FUBP1, a transcriptional activator of MYC, leading to MYC down- regulation which is required for aveolar type II cell differentiation. Blocks MDM2-mediated ubiquitination and degradation of p53/TP53. Functions as a proapoptotic factor.|
|Cellular Location||Cytoplasm, cytosol. Nucleus. Note=Following DNA damage, dissociates from the aminoacyl-tRNA synthase complex and translocates from the cytoplasm to the nucleus.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
AIMP2 was initially identified as a part of an aminoacyl-tRNA synthesase complex (1). It was later discovered to be a cofactor and substrate of Parkin, a Ring-type E3 ubiquitin ligase that is important for the survival of dopamine neurons in Parkinson’s disease; accumulation of AIMP2 in these cells lead to catecholaminergic cell death (2). AIMP2 can also bind to TRAF2, a key player in the TNF-alpha signaling pathway, causing the ubiquitination of TRAF2 by cIAP1, leading to TNF-alpha-dependent apoptosis (3). Finally, AIMP2 has been suggested to function as a tumor suppressor (4).
Quevillon S, Robinson JC, Berthonneau E, et al. Macromolecular assemblage of aminoacyl-tRNA synthetases: identification of protein-protein interactions and characterization of a core protein. J. Mol. Biol. 1999; 285:183-95.
Ko HS, von Coelln R, Sriram SR, et al. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J. Neruosci. 2005; 25:7968-78.
Choi JW, Kim DG, Park MC, et al. AIMP2 promotes TNFalpha-dependent apoptosis via ubiquitin-mediated degradation of TRAF2. J. Cell Sci. 2009; 122:2710-5.
Choi JW, UM JY, Kundu JK, et al. Multidirectional tumor-suppressive activity of AIMP2/p38 and the enhanced susceptibility of AIMP2 heterozygous mice to carcinogenesis. Carcinogenesis 2009; 30:1638-44.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.